Federated Hermes’s Protalix BioTherapeutics PLX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-5,761
| Closed | -$12.1K | – | 2199 |
|
|
2023
Q1 | $12.1K | Hold |
5,761
| – | – | ﹤0.01% | 1858 |
|
|
2022
Q4 | $7.89K | Hold |
5,761
| – | – | ﹤0.01% | 1892 |
|
|
2022
Q3 | $6K | Hold |
5,761
| – | – | ﹤0.01% | 1875 |
|
|
2022
Q2 | $6K | Hold |
5,761
| – | – | ﹤0.01% | 1883 |
|
|
2022
Q1 | $6K | Hold |
5,761
| – | – | ﹤0.01% | 1939 |
|
|
2021
Q4 | $5K | Hold |
5,761
| – | – | ﹤0.01% | 1993 |
|
|
2021
Q3 | $8K | Hold |
5,761
| – | – | ﹤0.01% | 2006 |
|
|
2021
Q2 | $11K | Hold |
5,761
| – | – | ﹤0.01% | 1978 |
|
|
2021
Q1 | $26K | Hold |
5,761
| – | – | ﹤0.01% | 1933 |
|
|
2020
Q4 | $21K | Hold |
5,761
| – | – | ﹤0.01% | 1904 |
|
|
2020
Q3 | $22K | Hold |
5,761
| – | – | ﹤0.01% | 1885 |
|
|
2020
Q2 | $22K | Hold |
5,761
| – | – | ﹤0.01% | 1855 |
|
|
2020
Q1 | $14K | Hold |
5,761
| – | – | ﹤0.01% | 1828 |
|
|
2019
Q4 | $19K | Hold |
5,761
| – | – | ﹤0.01% | 1842 |
|
|
2019
Q3 | $12K | Hold |
5,761
| – | – | ﹤0.01% | 1870 |
|
|
2019
Q2 | $27K | Hold |
5,761
| – | – | ﹤0.01% | 1768 |
|
|
2019
Q1 | $25K | Hold |
5,761
| – | – | ﹤0.01% | 1745 |
|
|
2018
Q4 | $18K | Hold |
5,761
| – | – | ﹤0.01% | 1790 |
|
|
2018
Q3 | $42K | Hold |
5,761
| – | – | ﹤0.01% | 1759 |
|
|
2018
Q2 | $25K | Hold |
5,761
| – | – | ﹤0.01% | 1776 |
|
|
2018
Q1 | $31K | Sell |
5,761
-16,410
| -74% | -$108K | ﹤0.01% | 1702 |
|
|
2017
Q4 | $147K | Sell |
22,171
-172,397
| -89% | -$1.16M | ﹤0.01% | 1556 |
|
|
2017
Q3 | $1.13M | Hold |
194,568
| – | – | ﹤0.01% | 1166 |
|
|
2017
Q2 | $1.63M | Sell |
194,568
-19,775
| -9% | -$186K | ﹤0.01% | 1017 |
|
|
2017
Q1 | $2.92M | Hold |
214,343
| – | – | 0.01% | 755 |
|
|
2016
Q4 | $954K | Buy |
+214,343
| New | +$958K | ﹤0.01% | 1151 |
|
|
2015
Q4 | – | Sell |
-650,362
| Closed | -$7.67M | – | 2139 |
|
|
2015
Q3 | $7.67M | Sell |
650,362
-95,295
| -13% | -$1.51M | 0.02% | 478 |
|
|
2015
Q2 | $14.5M | Sell |
745,657
-159,303
| -18% | -$3.3M | 0.04% | 391 |
|
|
2015
Q1 | $16.1M | Sell |
904,960
-29,490
| -3% | -$577K | 0.05% | 352 |
|
|
2014
Q4 | $17.2M | Sell |
934,450
-18,000
| -2% | -$387K | 0.05% | 325 |
|
|
2014
Q3 | $23M | Sell |
952,450
-41,834
| -4% | -$1.21M | 0.07% | 264 |
|
|
2014
Q2 | $36.3M | Sell |
994,284
-29,717
| -3% | -$1.2M | 0.11% | 178 |
|
|
2014
Q1 | $46.9M | Buy |
1,024,001
+1,471
| +0.1% | +$68.6K | 0.16% | 128 |
|
|
2013
Q4 | $39.8M | Sell |
1,022,530
-20,217
| -2% | -$851K | 0.14% | 148 |
|
|
2013
Q3 | $47.2M | Buy |
1,042,747
+5,398
| +0.5% | +$277K | 0.18% | 117 |
|
|
2013
Q2 | $50.9M | Buy |
+1,037,349
| New | +$55M | 0.2% | 104 |
|
Other funds holding PLX
N
Federated Hermes's PLX Position: Q2 2023 in Review
Federated Hermes sold out of Protalix BioTherapeutics (PLX) in Q2 2023, closing a stake of 5,761 shares — an estimated $12.1K sold.
Federated Hermes first reported a position in PLX in Q2 2013 and held it in 36 quarters. The position peaked at $50.9M in Q2 2013. 66 funds tracked by Wall St. Rank hold PLX as of Q2 2023.
- Federated Hermes reported no remaining Protalix BioTherapeutics position as of Q2 2023 after selling out during the quarter.
- Federated Hermes sold 5,761 Protalix BioTherapeutics shares in Q2 2023, an estimated $12.1K.
- Federated Hermes first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 36 quarters.
- Federated Hermes's Protalix BioTherapeutics position peaked at $50.9M in Q2 2013.
- 66 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2023.
Based on Federated Hermes's 13F filing for Q2 2023, filed 14 Aug 2023.